US Patent 10336824 Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
Patent 10336824 was granted and assigned to CytomX Therapeutics on July, 2019 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10336824 Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
